Your session is about to expire
← Back to Search
Device
iRF System Hepatic Denervation for Diabetes (DeLIVER Trial)
N/A
Waitlist Available
Research Sponsored by Metavention
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30, 90, 180 and 365 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new device that uses radio waves to target nerves in the liver. It aims to help people with type 2 diabetes control their blood sugar better.
Eligible Conditions
- Diabetes
- Type 2 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30, 90, 180 and 365 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30, 90, 180 and 365 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Rate of Serious Adverse Device Effects
Secondary study objectives
Adverse Event rate 365 days
Change in glycemic control - C-peptide
Change in glycemic control - FPG
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hepatic DenervationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iRF System Hepatic Denervation
2020
N/A
~20
Find a Location
Who is running the clinical trial?
MetaventionLead Sponsor
3 Previous Clinical Trials
121 Total Patients Enrolled
1 Trials studying Diabetes
46 Patients Enrolled for Diabetes
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger